Publication Name	World Journal of Virology
Manuscript ID	13790
Country	Pakistan

Received	2014-09-02 10:14
Peer-Review Started	2014-09-02 18:51
To Make the First Decision	2014-11-14 19:40
Return for Revision	2014-11-19 15:44
Revised	2014-12-03 16:39
Second Decision	2014-12-11 08:50
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-12-17 16:50
Articles in Press	2014-12-17 16:50
Publication Fee Transferred
Edit the Manuscript by Language Editor	2015-01-05 08:58
Typeset the Manuscript	2015-01-19 14:01
Publish the Manuscript Online	2015-01-20 22:09

ISSN	2220-3249 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Virology
Manuscript Type	Letter to the Editor
Article Title	Ledipasvir and sofosbuvir: Interferon free therapy for HCV genotype 1 infection
Manuscript Source	Invited Manuscript
All Author List	Yasir Waheed
Funding Agency and Grant Number
Corresponding Author	Yasir Waheed, PhD, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, H-12, Islamabad 44000, Pakistan. yasir_waheed_199@hotmail.com
Key Words	Hepatitis C; Interferon; Ledipasvir; Sofosbuvir; Genotype
Core Tip	The interferon based therapy for hepatitis C patients has a limited response with a number of adverse effects. The ledipasvir and sofosbuvir combination therapy showed a sustained virological response (SVR) rate of 99% in treatment na?ve patients. The rate of SVR was 94%-99% in treatment experienced patients, while in cirrhotic patients the rate of SVR was 86%-99%. The treatment response was not affected by ethnicity or host genetic factors.
Publish Date	2015-01-20 22:09
Citation	Waheed Y. Ledipasvir and sofosbuvir: Interferon free therapy for HCV genotype 1 infection. World J Virol 2015; 4(1): 33-35
URL	http://www.wjgnet.com/2220-3249/full/v4/i1/33.htm
DOI	http://dx.doi.org/10.5501/wjv.v4.i1.33

Full Article (PDF)	WJV-4-33.pdf
Full Article (Word)	WJV-4-33.doc
Manuscript File	13790-Review.docx
Answering Reviewers	13790-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	13790-Conflict-of-interest statement.pdf
Copyright License Agreement	13790-Copyright assignment.pdf
Peer-review Report	13790-Peer review(s).pdf
Scientific Misconduct Check	13790-CrossCheck.jpg
Scientific Editor Work List	13790-Scientific editor work list.pdf